Europäische Union - Deutsch - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostata-neoplasmen - endokrine therapie - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - degarelixum - pulver und lösungsmittel zur herstellung einer injektionssuspension (lösungsmittel in fertigspritze) - praeparatio cryodesiccata: degarelixum 80 mg ut degarelixi acetas 88.2 mg, mannitolum, pro vitro. solvens: aqua ad iniectabile 4.2 ml. - gnrh-rezeptorenblocker zur behandlung von prostatakarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - degarelixum - pulver und lösungsmittel zur herstellung einer injektionssuspension (lösungsmittel in fertigspritze) - praeparatio cryodesiccata: degarelixum 120 mg ut degarelixi acetas 128 mg, mannitolum, pro vitro. solvens: aqua ad iniectabile 3 ml. - gnrh-rezeptorenblocker zur behandlung von prostatakarzinom - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostata-neoplasmen - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.